Search Results

There are 39783 results for: content related to: Hand–foot syndrome induced by erlotinib ( T arceva Ⓡ )

  1. Dermatologic toxicities to targeted cancer therapy: shared clinical and histologic adverse skin reactions

    International Journal of Dermatology

    Volume 53, Issue 3, March 2014, Pages: 376–384, Jonathan L. Curry, Carlos A. Torres-Cabala, Kevin B. Kim, Michael T. Tetzlaff, Madeleine Duvic, Kenneth Y. Tsai, David S. Hong and Victor G. Prieto

    Version of Record online : 24 JUL 2013, DOI: 10.1111/ijd.12205

  2. You have free access to this content
    Oral therapy for nonmelanoma skin cancer in patients with advanced disease and large tumor burden: a review of the literature with focus on a new generation of targeted therapies

    International Journal of Dermatology

    Volume 55, Issue 3, March 2016, Pages: 249–258, Eric W. Rudnick, Sumeet Thareja and Basil Cherpelis

    Version of Record online : 13 NOV 2015, DOI: 10.1111/ijd.12961

  3. You have free access to this content
    Shikonin and its derivatives inhibit the epidermal growth factor receptor signaling and synergistically kill glioblastoma cells in combination with erlotinib

    International Journal of Cancer

    Volume 137, Issue 6, 15 September 2015, Pages: 1446–1456, Qiaoli Zhao, Nadine Kretschmer, Rudolf Bauer and Thomas Efferth

    Version of Record online : 6 MAR 2015, DOI: 10.1002/ijc.29483

  4. You have full text access to this Open Access content
    JAK2-related pathway induces acquired erlotinib resistance in lung cancer cells harboring an epidermal growth factor receptor-activating mutation

    Cancer Science

    Volume 103, Issue 10, October 2012, Pages: 1795–1802, Daijiro Harada, Nagio Takigawa, Nobuaki Ochi, Takashi Ninomiya, Masayuki Yasugi, Toshio Kubo, Hiromasa Takeda, Eiki Ichihara, Kadoaki Ohashi, Saburo Takata, Mitsune Tanimoto and Katsuyuki Kiura

    Version of Record online : 23 JUL 2012, DOI: 10.1111/j.1349-7006.2012.02363.x

  5. You have full text access to this Open Access content
    Substrate-dependent bidirectional modulation of P-glycoprotein-mediated drug resistance by erlotinib

    Cancer Science

    Volume 100, Issue 9, September 2009, Pages: 1701–1707, Kohji Noguchi, Haruka Kawahara, Airi Kaji, Kazuhiro Katayama, Junko Mitsuhashi and Yoshikazu Sugimoto

    Version of Record online : 12 MAY 2009, DOI: 10.1111/j.1349-7006.2009.01213.x

  6. You have free access to this content
    Synergistic effect of targeting the epidermal growth factor receptor and hyaluronan synthesis in oesophageal squamous cell carcinoma cells

    British Journal of Pharmacology

    Volume 172, Issue 18, September 2015, Pages: 4560–4574, I Kretschmer, T Freudenberger, S Twarock and J W Fischer

    Version of Record online : 30 JUL 2015, DOI: 10.1111/bph.13240

  7. Effect of erlotinib on epidermal growth factor receptor and downstream signaling in oral cavity squamous cell carcinoma

    Head & Neck

    Volume 35, Issue 9, September 2013, Pages: 1323–1330, Christina I. Tsien, Mukesh K. Nyati, Aarif Ahsan, Susmita G. Ramanand, Douglas B. Chepeha, Francis P. Worden, Joseph I. Helman, Nisha D'Silva, Carol R. Bradford, Gregory T. Wolf, Theodore S. Lawrence and Avraham Eisbruch

    Version of Record online : 21 AUG 2012, DOI: 10.1002/hed.23128

  8. Gene expression profiling on pre- and post-erlotinib tumors from patients with head and neck squamous cell carcinoma

    Head & Neck

    Volume 35, Issue 6, June 2013, Pages: 809–818, Fabienne Thomas, Paul Delmar, Sébastien Vergez, Philippe Rochaix, Isabelle Hennebelle, Patricia McLoughlin, Adil Benlyazid, Jérôme Sarini and Jean–Pierre Delord

    Version of Record online : 13 JUL 2012, DOI: 10.1002/hed.23036

  9. Coadministration of Erlotinib and Curcumin Augmentatively Reduces Cell Viability in Lung Cancer Cells

    Phytotherapy Research

    Volume 28, Issue 5, May 2014, Pages: 728–735, Yoshikane Yamauchi, Yotaro Izumi, Jun Yamamoto and Hiroaki Nomori

    Version of Record online : 13 AUG 2013, DOI: 10.1002/ptr.5056

  10. Population pharmacokinetics of erlotinib in Japanese patients with advanced non-small cell lung cancer

    Journal of Clinical Pharmacy and Therapeutics

    Volume 40, Issue 2, April 2015, Pages: 232–239, Y. Emoto-Yamamoto, S. Iida, T. Kawanishi and M. Fukuoka

    Version of Record online : 17 NOV 2014, DOI: 10.1111/jcpt.12232

  11. You have full text access to this Open Access content
    Salvage treatment with erlotinib after gefitinib failure in advanced non-small-cell lung cancer patients with poor performance status: A matched-pair case–control study

    Thoracic Cancer

    Volume 3, Issue 1, February 2012, Pages: 27–33, Daxian Luo, Meijuan Huang, Xinxing Zhang, Min Yu, Bingwen Zou, Yanying Li, Jianlin Long, Jin Wang, Feng Peng, Yong Xu, Lu Li, Li Ren, Mei Hou and You Lu

    Version of Record online : 5 FEB 2012, DOI: 10.1111/j.1759-7714.2011.00087.x

  12. You have free access to this content
    First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer

    Intervention Review

    The Cochrane Library

    Janette Greenhalgh, Kerry Dwan, Angela Boland, Victoria Bates, Fabio Vecchio, Yenal Dundar, Pooja Jain and John A Green

    Published Online : 25 MAY 2016, DOI: 10.1002/14651858.CD010383.pub2

  13. You have free access to this content
    Reply

    Hepatology

    Volume 61, Issue 2, February 2015, Pages: 729–730, Bryan C. Fuchs, Yujin Hoshida and Kenneth K. Tanabe

    Version of Record online : 31 JUL 2014, DOI: 10.1002/hep.27208

  14. Identifying novel targets of oncogenic EGF receptor signaling in lung cancer through global phosphoproteomics

    PROTEOMICS

    Volume 15, Issue 2-3, January 2015, Pages: 340–355, Xu Zhang, Natalya Belkina, Harrys Kishore Charles Jacob, Tapan Maity, Romi Biswas, Abhilash Venugopalan, Patrick G. Shaw, Min-Sik Kim, Raghothama Chaerkady, Akhilesh Pandey and Udayan Guha

    Version of Record online : 15 JAN 2015, DOI: 10.1002/pmic.201400315

  15. Evaluation of the Absolute Oral Bioavailability and Bioequivalence of Erlotinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in a Randomized, Crossover Study in Healthy Subjects

    The Journal of Clinical Pharmacology

    Volume 46, Issue 3, March 2006, Pages: 282–290, Dr Paul Frohna, Dr Jianfeng Lu, Dr Steve Eppler, Dr Marta Hamilton, Ms Julie Wolf, Dr Ashok Rakhit, Dr Jie Ling, Dr Saraswati R. Kenkare-Mitra and Dr Bert L. Lum

    Version of Record online : 8 MAR 2013, DOI: 10.1177/0091270005284193

  16. Impact of nutritional status on the pharmacokinetics of erlotinib in rats

    Biopharmaceutics & Drug Disposition

    Volume 36, Issue 6, September 2015, Pages: 373–384, A. Pérez-Pitarch, A. Nácher, V. Merino, A. Catalán-Latorre, N.V. Jiménez-Torres and M. Merino-Sanjuán

    Version of Record online : 16 APR 2015, DOI: 10.1002/bdd.1948

  17. You have free access to this content
    Delay of treatment change after objective progression on first-line erlotinib in epidermal growth factor receptor-mutant lung cancer

    Cancer

    Volume 121, Issue 15, August 1, 2015, Pages: 2570–2577, Peter C. Lo, Suzanne E. Dahlberg, Mizuki Nishino, Bruce E. Johnson, Lecia V. Sequist, David M. Jackman, Pasi A. Jänne and Geoffrey R. Oxnard

    Version of Record online : 15 APR 2015, DOI: 10.1002/cncr.29397

  18. ERLOTINIB ACTIVATES MITOCHONDRIAL DEATH PATHWAYS RELATED TO THE PRODUCTION OF REACTIVE OXYGEN SPECIES IN THE HUMAN NON-SMALL CELL LUNG CANCER CELL LINE A549

    Clinical and Experimental Pharmacology and Physiology

    Volume 36, Issue 5-6, May/June 2009, Pages: 487–494, Xia Qian, Jing Li, Jianhua Ding, Zhiyuan Wang, Wenjing Zhang and Gang Hu

    Version of Record online : 8 OCT 2008, DOI: 10.1111/j.1440-1681.2008.05091.x

  19. HRAS mutations and resistance to the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in head and neck squamous cell carcinoma cells

    Head & Neck

    Volume 36, Issue 11, November 2014, Pages: 1547–1554, J. Hun Hah, Mei Zhao, Curtis R. Pickering, Mitchell J. Frederick, Genevieve A. Andrews, Samar A. Jasser, David R. Fooshee, Zvonimir L. Milas, Chad Galer, Daisuke Sano, William N. William Jr, Edward Kim, John Heymach, Lauren A. Byers, Vali Papadimitrakopoulou and Jeffrey N. Myers

    Version of Record online : 20 MAR 2014, DOI: 10.1002/hed.23499

  20. Activity of erlotinib when dosed below the maximum tolerated dose for EGFR-mutant lung cancer: Implications for targeted therapy development

    Cancer

    Volume 122, Issue 22, November 15, 2016, Pages: 3456–3463, Benjamin L. Lampson, Mizuki Nishino, Suzanne E. Dahlberg, Danie Paul, Abigail A. Santos, Pasi A. Jänne and Geoffrey R. Oxnard

    Version of Record online : 15 AUG 2016, DOI: 10.1002/cncr.30270